Madeline A. Henn

发表

A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice

S. Mousses, B. Park, J. Kim, 2021, Science Translational Medicine.

Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer

Joy J. Chen, Liqian Ma, Madeline A. Henn, 2020, bioRxiv.

The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.

Liqian Ma, M. Spinella, D. Gewirtz, 2022, Biochimica et biophysica acta. Molecular basis of disease.

Analysis of Gene Expression Heterogeneity Reveals Therapeutic Targets and Novel Regulators of Metastasis

G. Balázsi, M. Rosner, Dongbo Yang, 2022, bioRxiv.

27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Joy J. Chen, Liqian Ma, Lawrence Wang, 2020, Cancer Letters.

The cholesterol metabolite 27-hydroxycholesterol increases the secretion of extracellular vesicles which promote breast cancer progression.

Janet E. Sorrells, S. Boppart, H. Kong, 2021, Endocrinology.

Re-education of myeloid immune cells to reduce regulatory T cell expansion and impede breast cancer progression

Liqian Ma, Hong Chen, F. Végran, 2023, bioRxiv.

Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.

F. Végran, R. Boidot, Madeline A. Henn, 2024, Cancer letters.

OR05-01 Small Heterodimer Partner Modulates Antigen Presenting Myeloid Cells to Impair Regulatory T Cell Expansion, Promoting Anti-Tumor Immunity in Models of Breast Cancer

Joy J. Chen, Liqian Ma, Madeline A. Henn, 2020, Journal of the Endocrine Society.

NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.

F. Végran, R. Boidot, Madeline A. Henn, 2024, Cancer letters.